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1. Introduction
DNA methylation is a major epigenetic modification that is strongly involved in the physio‐
logical control of genome expression. Developmental processes and proper biological func‐
tions are tightly dependent on hierarchical and regulated gene expression patterns. Numerous
molecular processes control gene expression. DNA methylation is a physiological epigenetic
process that leads to long term-repression of gene expression. DNA methylation is a common
epigenetic modification involving the methylation of 5'-cytosine residues and is often detected
in the dinucleotides of CpG sequences. Methylation is often localized in promoter regions and
occasionally in transcriptional regulatory regions in mammals, plants and even prokaryotes.
DNA methylation may be classified as hyper-and hypomethylation, according to increased
and decreased levels of genomic modification, respectively. Hypermethylation is an epigenetic
alteration often leading to gene-inactivating deletions and translocations. Hypermethylated
cells may exhibit a phenotype of drug-resistance or malignant proliferation. Aberrant meth‐
ylation in eukaryotic cells may lead to silencing of important genes, such as tumour suppressor
genes, affecting their related transcriptional pathways and ultimately leading to the develop‐
ment of disease such as cancer. Therefore, it is considered to be a hallmark of cancer, it is
detected in several types of cancer cells, including colon, breast, ovarian and cervical cancer
cells and is associated with alterations in specific gene expression.
Hypermethylation of tumour suppressor gene promoters and global disruption of many
histone modifications are characteristic features of cancer. Deregulation of the epigenetic
profile alters the transcription profile of many genes. In the case of tumour suppressors DNA
methylation reduces gene expression and subsequently removes regulatory proteins required
for normal cell growth and development. Therefore, DNA methylation in cancer would be
predicted to influence multiple gene networks rather than single genes. Because of heteroge‐
neity of breast cancer at both histological and molecular levels staging breast cancer fails to
predict prognosis or therapeutic response of the disease, therefore, DNA methylation targeted
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therapies, in recent years, play an increased role in the treatment of breast cancer. DNA
methylation targeted therapies, in recent years, play an increased role in the treatment of breast
cancer. Two groups of agents targeting epigenetic modifications have been studied previously,
namely histone deacetylase inhibitors and DNA methyl transferase inhibitors. The associations
between DNA methylation mechanism and breast cancer classification and prognosis will be
reviewed in this chapter in detail by describing the DNA methylation mechanism and gene
expression in breast cancer, as well as functional genomics and genome wide DNA methyla‐
tion in breast cancer.
2. What is epigenetics?
The term epigenetic was introduced by Conard Waddington in 1942 as a concept of environ‐
mental influence in inducing phenotype modification. His work on developmental plasticity
states that the environmental influences during development could induce alternative
phenotypes from one genotype, one of the clearest examples is polyphenisms in insects. He
showed that exposing the pupae of wild type Drosophila melanogaster to heat shock treat‐
ment, results in altered wing vein patterns [1,2]. Breeding individuals who have been exposed
to these environmentally induced changes led to a stable population exhibiting the phenotype
without the environmental stimulus. The concept of epigenetics was not clarified until the late
1990s when Wolffe and Matzkeset the modern definition, which was ‘the study of heritable
changes in gene expression that occur without a change in DNA sequence’[4]. Bird came with
a wider definition of epigenetic which is ‘the structural adaptation of chromosomal regions so
as to register, signal or perpetuate activity states’ [5]. The term epigenome has emerged to
describe the epigenetic modifications all over the epigenome, thus, the epigenome controls the
genome in both normal and abnormal cellular processes and events [6]. Epigenetic mecha‐
nisms include; DNA methylation, histone modification and non-coding RNAs, which work
cooperatively to control gene expression.
3. DNA methylation
DNA methylation is a well conserved process that occurs in eukaryotes and prokaryotes [7].
DNA methylation refers to the covalent addition of a methyl group to carbon number five in
the nitrogenous base cytosine at the DNA strand. Only cytosine residues where adjacent to
guanine are targets for the methylation by the methyltransferases enzymes and the distribution
of methylated and unmethylated CpGs is tissue-specific which leads to cell-specific pattern of
DNA methylation [8]. The CpG may occur in multiple repeats which are known as CpG islands
[9]. These regions are often associated with the promoter regions of genes. Almost half of the
genes in our genome have CpG rich promoter regions. In the whole genome, about 80% of the
CpG dinucleotides not associated with CpG islands are heavily methylated [10]. In contrast,
the CpG islands associated with gene promoters are usually unmethylated [11].
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There are a number of factors that may maintain the undermethylated state of CpG islands,
such as sequence feature, SP1 binding sites, specific acting enhancer elements, as well as
specific histone methylation mark H3K4me3, which prevents the binding of de novo methyl‐
ation complexes [12]. Methylation of the CpG islands in the promoter region silences gene
expression, and the absence of methylation is associated with active transcription. Thus
unmethylated CpG islands are associated with the promoters of transcriptionally active genes,
such as housekeeping genes and many regulated genes, such as genes showing tissue specific
expression [13]. DNA methylation information at every cytosine can be determined, but it was
targeted at few candidate genes using methylation-sensitive restriction enzymes or gene-
specific DNA methylation mapping by sequencing bisulfite-converted DNA. In contrast,
development of advance technology in DNA methylation mapping, including high-density
oligonucleotide arrays, illumina bead arrays and next-generation high-throughput sequenc‐
ing, together with advances in bioinformatics, have enable examination of broad regions of
the genome and provide high-content profiles of DNA methylation.
3.1. DNA Methyltransferases (DNMTs)
The methylation process is catalysed by the DNA methyltransferases enzymes (DNMTs)
which are known as DNMTs; DNMT1, DNMT3A, DNMT3B, and DNMT3L [14]. DNMT3A
and DNMT3B are the de novo methyltransferases while DNMT1 maintains the methylation
patterns during DNA replication (mitosis) [15]. However, the actual function of DNMT2 is not
clear, bur several forms of DNMT1 have been detected which differ in their translation start
sites and prefer hemimethylated DNA. Overexpression of DNMT1 has been reported in
human tumours and may contribute to the global methylation abnormalities seen in cancer
cells although increased expression of the DNMTs is likely to be only partially responsible for
the observed methylation abnormalities since not all tumours overexpress these enzymes [10].
Cytosine (C5)-DNA methyltransferases catalyze the transfer of a methyl group from S-
adenosyl-methionine onto cytosine residues in specific sequences of duplex DNA, with
production of 5-methyl cytosine and S-adenosyl-homocystein (SAMe) (Figure1). For most
proteins, cytosine (C5)-DNA methyltransferases have up to 10 conservative regions arranged
in a strictly defined sequence [16]. Comparison of the primary structures of cytosine (C5)-DNA
methyltransferases reveals the association of their major functions with their conservative
motifs, whereas the site-specific recognition belongs to a variable region of the target-recog‐
nizing domain (TRD) [17]. Among ten conservative blocks of amino acids in cytosine (C5)-DNA
methyltransferases, the N-terminal domain of DNMT1 contains varied specific functional
sequences, such as the nuclear localization signal (NLS), the cysteine–enriched zinc-binding
motif, and a special sequence directing the methylase into the area of DNA replication. In
addition, DNMT1 interact with the proliferating cell nuclear antigen (PCNA) which is required
for DNA replication, and the DNMT1-PCNA interaction allow rapid remethylation of the
newly synthesised daughter strands before packed into chromatin [18]. A null mutation of the
mouse methylase DNMT1 gene resulted in a significant (up to 70%) decrease in the genome
methylation and death of developing embryos [19]. The remaining 30% level of DNA meth‐
ylation and the ability of embryonic stem cells deprived of the DNMT1 methylase for de novo
methylation of DNA suggest that these functions were performed by other DNA methylases
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[19]. Such methylases were searched for in animals, and new enzymes of the DNMT2 and
DNMT3 families were found [20]. Cell-cycle regulators p21 and retinoblastoma gene product
Rb can bind to DNMT1 and inhibit its methyltransferase activity during DNA replication in
the cell cycle [18]. This observations show complex interaction between DNMT1 and cellular
proteins involved in gene regulation and epigenetic signalling during cell replication [21].
The DNMT3 family consists of two genes, DNMT3a and DNMT3b, which are highly expressed
in undifferentiated ES cells but downregulated after differentiation and expressed at low levels
in adult somatic tissues and are overexpressed in tumour cells [22]. Both DNMT3a and
DNMT3b are required for genome-wide de novo methylation and are essential for mammalian
development [22]. Both DNMT3a and DNMT3b had been mapped by the unigene consortium
via polymorphisms in 3' –untranslated region sequences. DNMT3b mapped to the region of
chromosome 20q that contains the trait for ICFNS (immunodeficiency centromeric instability,
facial ubnormalities) syndrome. This syndrome presents with variable combined immunode‐
ficiency, mild facial anomalies and extravagant cytogenetic abnormalities which largely affect
the pericentric region of chromosomes 1, 9 and 16. These pericentric regions contain a type of
satellite DNA termed classical satellite, or satellites 2 and 3. It is normally heavily methylated,
but is nearly completely unmethylated in the DNA of ICF patients. It was found that immu‐
nodeficiency centromeric instability (ICF) patients had mutations in the C-terminal DNA
methyltransferase domain of DNMT3b. DNMT3b remains the only DNA methyltransferase
shown to be mutated in a human disease [15]. DNMT3b has been shown to play a crucial role
in hypermethylation of promoter CpG-rich regions of tumour suppressor genes and thus its
inactivation within human cancer cells [22].
3.2. How does demethylation occur?
The key question is how the enzymes know where to methylate? Two theories have been
suggested. Firstly, it has been suggested that all genes are methylated by default except for
active genes [23]. Actively transcribed genes have a preponderance of attached transcriptional
factors, giving no physical access to the methyltransferses to reach their targets. On the other
hand, inactive DNA is susceptible to the methyltransferases and subsequently become
methylated. This model was confirmed by the study of the transcription factor SP1. It has been
shown that as long as SP1 is attached to its site, no methylation could occur in the adjacent
CpG sites, and removal of the SP1 leads to de novo methylation at this site [24]. The second
theory is that methylation is directed by sequence specific binding proteins so the methyl‐
transferases bind with certain proteins such as a histone deacetylases (HDACs) and other
transcription repressors, and form a complex would bind to specific sequence on the DNA [23].
Methylated genes may need to be activated in response to environmental signals and thus
demethylation is an important dynamic epigenetic mechanism and it was originally thought
that demethylation only occured through passive demethylation (Figure 2). However, the
rapid demethylation of the paternal genomes upon fertilization and examples of rapid
demethylation of genes in post-mitotic neurons suggest that an active demethylase must exist
[23,25]. A number of enzymes have been suggested to have demethylase activity these include
MBD2b, MBD4, the DNA repair endonucleases XPG (Gadd45a) and a G/T mismatch repair
A Concise Review of Molecular Pathology of Breast Cancer30
DNA glycosylase which is glycosidase dependent. In this mechanism, the methylated cytosine
is recognized by glycosidase which cleaves the bond between the DNA back bone and base.
The base is subsequently removed and replaced with unmethylated cytosine by the DNA
repair system.
4. Histone Deacetylases (HDACs)
Histones are five basic nuclear proteins that form the core of the nucleosome and the histone
octamer contains two molecules each of histones H2A, H2B, H3 and H4. Histone H1 the linker
histone is located outside the core and involve in the packing of DNA [26]. Histone modifica‐
tions play a major role in regulating gene expression and extend the information potential of
the DNA which explains the growing interest of the ‘Histone Code’ [27]. Modifications to
amino acids on the N-terminal tails of histones protruding from the nucleosome core can
induce both an open or closed chromatin structure and these affect the ability of transcription
factors to access promoter regions to activate transcription. The covalent modification can be
acetylation, methylation, phosphorylation and ubiquitination. Methylation of some residues
is associated with both transcriptional repression, such as methylation of histone 3 lysine 9 (H3
K9) and others with transcriptional activation, such as methylation of histone 3 lysine 4 (H3
K4) [28,29].
Histone methylation is performed by histone methltransferase (HMTs) which can transfer up
to three methyl groups to lysine residues within the tails of the histones with different effects
on gene activity. Acetylation which occurs at lysine residue is associated with transcriptional
activation [30]. This modification is performed by histone acetylases (HATs) and removed by
the HDACs [31]. The HDACs are critical in the regulation of expression of genes important for
cell survival, proliferation, differentiation, and apoptosis [32]. HDACs also act as members of
a protein complex responsible for recruitment of transcription factors to the promoter region
of genes, including those of tumour suppressors, and regulation of acetylation status of specific
cell cycle regulatory proteins [33]. High HDAC expression and histone hypoacetylation have
been observed in cancer with associated transcriptional repression of genes, providing a
rationale for the investigation of HDAC inhibitors in cancer therapeutics [34].
Additionally, acetylation of histones has been extensively studied as one of the key regulatory
mechanisms of gene expression [35]. Histone acetylation was found to affect RNA transcription
as early as the 1960s [36]. The highly conserved lysine residue at the N-terminal of H3 at
position 9, 14, 18 and 23, and H4 lysine 5,8,12 and 16, are frequently targeted for modification
[37]. Acetylations of the lysine residues neutralize the positive charge of the histone tails.
Therefore, decrease their affinity for DNA which results in open chromatin conformation
allowing the transcriptional machinery to reach its target [38]. The acetyltransferases added
the acetyl groups from acetyl coenzyme A (acetyl-CoA) to the epsilon-amino group of specific
lysine residues [39]. There are eighteen HDAC enzymes in mammalian cells which are divided
into two families: a) zinc metalloenzymes that catalyses the hydrolysis of acetylated specific
residues on histone tails and include class I, II and 1V HDACs, and b) NAD-dependent Sir2
deactylases which are considered as class III HDACs [40,41].
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Class I is a group of four enzymes known as HDAC1, 2, 3 and 8 and this class is associated
with gene regulation. They are expressed ubiquitously and they function exclusively in the
nucleus [40]. Class II is subdivided into class IIA, which includes HDAC 4, 5, 7 and 9 and class
IIB that includes HDAC 6 and 10. Class II enzymes shuttle between cytoplasm and nucleus,
and they involve mainly in cell differentiation and are highly expressed in certain tissues [40].
Class III includes the NAD-dependent deacetylases which is a group of seven enzymes that
are involved in maintaining the chromatin stability. They can remove the acetyl groups from
histones besides other proteins [42]. Class IV contains one member which is HDAC11 which
is closely related to class I thus some reviewers consider it as a member of that class. The
function of HDAC11 has not been characterized yet [43], however, there is increasing evidence
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Figure 1. Methylation of DNA by DNA methyltransferases enzymes (DNMTs) DNMT1, DNMT3A, DNMT3B. A meth‐
yl group transfer from S-adenosyl-methionine onto cytosine residues leading to production of 5-methyl cytosine and S-
adenosyl-homocystein (SAMe).
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Figure 2. DNA demethylation appears to be a shared attribute of reprogramming events, and understanding DNA
methylation dynamics is thus of considerable interest. Some enzymes such as MBD2b and MBD4 convert 5-methylcy‐
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showing that changes in chromatin structure would alter DNA methylation patterns. The
targeting of DNA methylation enzymes to gene promoters is guided by chromatin modifying
enzymes. The fact is that chromatin configuration is dynamic and that chromatin modifying
enzymes are activated by cellular signalling pathways. This provides a link between the
extracellular environment and the state of DNA methylation [44]. Evidence of the link between
chromatin modelling and DNA methylation in humans and mice arises from mutations of the
SWI-SNF proteins which are involved in chromatin remodelling. These mutations result in
defects in DNA methylation [44]. A number of histone methyltransferases, such as G9a,
SUV39H1 and EZH2, a member of the multi-protein polycomb complex PRC2 can regulate
DNA methylation by either recruiting or regulating the stability of DNMTs. DNMTs in turn
can recruit HDACs and MBPs to achieve chromatin condensation and gene silencing [45]. This
relationship between the epigenetic machinery makes the epigenetic mechanisms of genome
expression a tightly regulated process.
5. DNA methylation and breast cancer
During the last decade, the study of epigenetic mechanisms in cancer, such as DNA methyla‐
tion, histone modification, nucleosome positioning, and micro RNA expression, has provided
extensive information about the mechanisms that contribute to the neoplastic phenotype
through the regulation of expression of genes critical to transformation pathways. Regarding
DNA methylation, the low level of CpG methylation in tumours compared with that in their
normal-tissue counterparts was one of the first epigenetic alterations to be found in human
cancer this let us to think that the cancer cells have a specific epigenome [46]. Hypomethylation
in cancer cells is associated with a number of adverse products, including chromosome
instability, activation of transposable elements, and loss of genomic imprinting [47].
Breast cancer has traditionally been staged by histopathological standards that are based on
size, level of invasiveness and lymph node infiltration, and by immunochemical characteri‐
zation of cell surface receptors, including oestrogen receptor (ER), the progesterone receptor
(PR) and the human epidermal growth factor receptor 2 (HER2). However, in many instances
staging breast cancer fails to predict prognosis or therapeutic response because of the hetero‐
geneity of the disease. Changes in gene expression that reset a cell program from a normal to
a diseased state involve multiple genetic circuitries, creating a characteristic signature of gene
expression that defines the cell's unique identity and to classify subtypes of breast cancers [48].
Detailed knowledge of the DNA methylation status of all cytosines (the methylome) is
paramount for understanding the mechanisms and functions underlying DNA methylation
and led to extend our ability to classify breast cancer and the outcome prediction. DNA
methylation is a forceful biomarker, greatly more stable than proteins or RNA, and is therefore
a promising target for the development of new approaches for diagnosis and prognosis of
breast cancer and other diseases. Because DNA methylation is critical in gene expression
programming, a change in methylation from a normal to diseased state should be similarly
reflected in a signature of DNA methylation that involves multiple gene pathways. Whole-
genome approaches have been used with different levels of success to distinguish breast-
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cancer-specific DNA methylation signatures, and to test whether they can classify breast cancer
and whether they could be associated with specific clinical outcomes [48].
Application of DNA methylation profiling becomes important for breast cancer diagnosis and
prognosis only if it provides additional classification value to other currently used methods
like immunohistochemistry and mRNA expression analysis. A recent whole-genome DNA
methylation analysis by using the Illumina 27 K arrays suggests that DNA methylation
profiling might expand current classifications of breast cancer subtypes [49,50]. The analysis
of 248 breast cancer tumour samples, comprising a 'main set' of 123 samples (4 normal and 119
infiltrating ductal carcinomas (IDCs)), and a 'validation set' of 125 samples (8 normal and 117
IDCs), revealed an immune 'signature' in a mixed tumour stromal population, as also reported
[51]. Methylome analysis performed on frozen primary tumour samples, led to the identifica‐
tion of six different methylation clusters [52]. It was shown for the first time that DNA
methylation profiles can reflect the cell-type composition of the tumour microenvironment,
with a T lymphocyte infiltration of these tumours in particular in HER2-enriched and basal-
like tumours. High expression of certain immune-related genes were found to be associated
with improved relapse-free survival providing further insight into the importance of the
immune system and tumour microenvironment in certain breast cancer subtypes [53].
Furthermore, aberrations in DNA methylation patterns of the CpG islands in the promoter
regions of tumour-suppressor genes are accepted as being a common feature of human cancer
[54]. CpG island promoter hypermethylation affects genes from a wide range of cellular
pathways, such as cell cycle, DNA repair, toxic catabolism, cell adherence, apoptosis, and
angiogenesis, among others [54], and may occur at various stages in the development of cancer
[55]. The CpG-island-containing gene promoters are usually unmethylated in normal cells to
maintain euchromatic structure, which is the transcriptionally active conformation allowing
gene expression. Yet, during cancer development, many of these genes are hypermethylated
at their CpG-island-containing promoters to inactivate their expression by changing open
euchromatic structure to compact heterochromatic structure [56,57]. These genes are selec‐
tively hypermethylated in tumourigenesis for inactivation owing to their functional involve‐
ment in various cellular pathways that prevent cancer formation. Some of the methylated genes
identified in human cancers are classic tumour suppressor genes in which one mutationally
inactivated allele is inherited. According to Knudson's (2000) two-hit model, complete
inactivation of a tumour suppressor gene requires loss-of-function of both gene copies [58].
Epigenetic silencing of the remaining wild-type allele of the tumour suppressor gene, thus,
can be considered as the second hit in this model. For example, some well-known tumour
suppressor genes, such as the cyclin-dependent kinase inhibitorp16INK4a, APC and BRCA1,
are mutationally inactivated in the germline occasionally lose function of the remaining
functional allele in breast epithelial cells through DNA hypermethylation [59].These advances
in the knowledge of the breast methylome strongly indicate that DNA hypermethylation
mechanism plays a crucial role in initiation, promotion and maintenance of breast carcino‐
genesis, which cooperatively and synergistically interact with other genetic alterations to
promote the development of breast cancer. In addition to cell-cycle regulatory genes, DNA
methylation-mediated silencing of DNA repair genes, such as BRCA1 and MGMT, could result
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in further inactivation of tumour suppressor genes or activation of oncogenes, which further
drive breast tumourigenesis [60]. The genes that function as inhibitors of WNT oncogenic
pathway such as SFRP1 and WIF1 have been found to be frequently hypermethylated in
primary breast tumours [61]. Accordingly, epigenetic gene silencing is another mechanism
that fosters malignant transformation of the mammary gland by aberrantly activating onco‐
genic signalling pathways in addition to the genetic mutation-mediated mechanism [62].
In vitro experiments showed that decreased BRCA1expression in cells led to increased levels
of tumour growth, while increased expression of BRCA1 led to growth arrest and apopto‐
sis.  The magnitude of  the  decrease  of  functional  BRCA1 protein correlates  with disease
prognosis  [63].  Phenotypically,  BRCA1-methylated tumours are similar  to tumours from
carriers of germline BRCA1 mutations. BRCA1 promoter hypermethylation was observed
in one of two tumours from BRCA1 carriers lacking LOH [64]. In other study of population-
based  ovarian  tumours,  two  of  eight  tumours  with  germline  BRCA1mutations  showed
neither  LOH nor  promoter  methylation  [65].  Another  study  of  47  breast  tumours  from
hereditary  breast  cancer  families  identified  three  BRCA1 carriers  of  which  two showed
BRCA1 promoter  methylation  in  their  tumours  [66].  All  these  investigated  studies  sug‐
gest that methylation of BRCA1 may be serve as a second hit in tumours from a subset of
BRCA1 mutation carriers [67].Tumours with BRCA1 mutations are usually more likely to
be higher-grade, poorly differentiated, highly proliferative, ER negative, and PR negative,
and p53 mutations. BRCA1 mutated breast cancers are also associated with poor survival
in some studies [68]. BRCA1 promoter methylation was more frequent in invasive than in
situ carcinoma and there were no correlation between BRCA1 promoter methylation and
ER/PR status in a subset population [69]. However, they also found a higher prevalence of
BRCA1 promoter methylation in cases with at least one node involved and with tumour
size greater than 2cm. Based on their findings higher methylation levels may correlate with
more advanced tumour stage at diagnosis. They also observed a 45% increase in mortali‐
ty  of  individuals  with  BRCA1  methylation  positive  tumours  compared  those  who  had
unmethylated BRCA1 promoters  [69].  Another  study conducted a  familial  breast  cancer
based study and found contradicting results. They found no overall correlation of ER, PR,
or grade with hypermethylation of  BRCA1 in the tumours from BRCA1 mutation nega‐
tive families. However, seven individuals had both promoter hypermethylation and LOH;
the majority of these tumours had a basal-like phenotype and were triple negative [70].
In addition, discriminate between tumour and normal or histologically non-malignant breast
tissue has been applied widely by genome wide DNA methylation. One of the first genome
wide DNA methylation studies in breast cancer developed methylation-specific digital
karyotyping (MSDK) to assess epithelial, myoepithelial, and stromal fibroblasts from normal
abreast and cancer tissues [71]. Furthermore, genome wide DNA methylation studies in breast
cancer identified gene families that were commonly identified as differentially methylated
between non-malignant and tumour included transcription factors (FOX, KLF, PRDM, ZBTB,
and ZNF) and gene families involved in cell transport of proteins or vesicles(RAB and SLC)
or involvement in cell adhesion (CDH and PCDH) [71-74]. The pathways and gene families
do not appear to have a strong link to hormone metabolism or signalling, it is likely that these
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genes are not drivers of cancer but rather are secondary events that occur as part of the
tumourigenic process [75,76].
Genome wide DNA methylation studies have supported correlation between DNA methyla‐
tion and gene expression, particularly the association between CpG islands DNA hyperme‐
thylation and gene repression [49,74,77,78]. Using familial breast cancers and BRCA1/2-
mutated tumours combined DNA methylation profiles that alone predicted BRCA status, with
gene expression and copy number variation (CNV) and found that genes with reduced
expression were more likely to be in genomic regions with loss of heterozygosity and/or high
levels of DNA methylation. It has also been shown that the combination of gene dosage in
breast cancer cell lines, allelic status, and DNA methylation explains more gene expression
changes than either genomic element alone [79]. Combining DNA methylation profiling with
CNV and gene expression can be promising tool to facilitate the identification of critical genes
involved in tumourigenesis. In genome wide methylation analysis, several platforms have
been recently developed to allow genome wide methylation analysis. The Golden Gate
methylation array was the first platform which allowed methylation of 1536 CpG loci to be
investigated. The Infinium Human Methylation 27 increased CpG investigation with the use
of 27,578 probes. Most recently was the Infinium Human Methylation 450K array, designed
by Illumina. This array utilises florescence microarray hybridisation technique, often associ‐
ated with expression studies, to provide a methylation profile of 485,764 CpG loci including
CpG associated in CpG islands, shores, shelves and the isolated loci in the open sea regions of
the genome and promoter regionshave used Illumina Infinium Human Methylation 27 Bead
Chip to analyse normal breast tissues from ten healthy individuals and compared this to 62
breast tumour samples (19 were inflammatory breast cancer) [73].
Further studies have also compared tumour to non-malignant tissue and the number of genes
identified that discriminates the two depends on the filtering or analyses utilized. For instance,
Kim et al. (2012) used several filtering processes to identify six genes [80], whereas, Faryna et
al, (2012) identified 214 CpG islands but only one CpG island (TAC1) was methylated in all
ten cancer samples [81]. The DNA methylation profiles divided the samples into three groups
based on high, intermediate, and low DNA methylation levels, with the normal samples
having low DNA methylation levels. When comparing DNA methylation between normal and
tumour samples, 1352 CpG loci (1134 genes) were differentially methylated [73]. There was
significantly greater methylation in tumours compared with normal and 77% of these are CpG
loci. Another study using the same technology found 6309 CpGs differentially methylated
between 119 tumours and four normal breast tissue samples identified several hundred
differentially methylated loci between 11 adjacent non-malignant breast tissues and 108
tumours [49;74]. Kim et al, (2011) pooled DNA from ten cancers and ten non-malignant
matched adjacent tissues and identified 1181 differentially methylated CpGs (corresponding
to 1043 genes) with the vast majority (972) hypermethylated [82]. Another study found 291
probes (264 genes) hypermethylated in breast cancer (n=39) compared with non-malignant
breast tissue (n=4) after removal of imprinted genes and X chromosome genes [83].
In addition, numbers of studies have investigated whether genome wide DNA methylation
profiling can cluster breast cancers into hormone receptor status (ER/PR positive or negative)
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or subtype (luminal A or B, basal or HER2). These investigations differentiate hormone
receptor-positive breast cancers from hormone receptor-negative cases using DNA methyla‐
tion profiles [49,77,83-85]. The majority of genome wide DNA methylation studies have found
that ER+PR+tumours have higher levels of DNA methylation compared with ER−PR− tumours
[77,82,85,86]. Li et al, (2010) found 148 altered CpG sites (93 hypermethylated and 55 hypo‐
methylated) in ER+PR+breast cancers relative to ER−PR− tumours [85]. Other study have
identified 40 CpG probes that had an overall specificity of 89% and sensitivity of 90% for
classifying ER+from ER− tumours [86].
Moreover, Hill et al, (2011) have used cluster analysis to show that ER+PR+tumours had high
methylation, whereas triple-negative breast cancers had low methylation status [83]. Breast
cancer cell lines have also shown clustering according to hormone receptor status based on
DNA methylation levels [78]. Thus, all these genome wide DNA methylation studies demon‐
strate that an adequately results of appropriate clinical samples should identify methylation
differences based on hormone receptor status. These studies may serve with additional future
studies as a basis for the development of an improved clinical test to identify the hormone
status of breast cancers.
In addition, in DNA methylation cluster analysis found that one cluster was predominantly
luminal A (22/30 samples), the second cluster was highly correlated with basal-like (7/8
samples), and the third cluster contained a mixture of subtypes [74]. Recently, the Cancer
Genome Atlas (TCGA) [87] and genome-wide profiling of DNA methylation has been also
performed in primary breast tumours and revealed genes whose hypermethylation was
significantly correlated with relapse-free survival, including RECK, SFRP2 and ACADL.
Tumour specificity of methylation was confirmed for these genes by sequencing of an
independent set of normal/breast tumour samples. Other investigation observed that the
reduction of RECK methylation has been associated with worst prognosis in other tumours
[88]. Genome-wide analysis has also been employed to characterize the DNA methylation
profile of primary breast cancer with different metastatic potential. A global breast CpG island
methylation phenotype (B-CIMP) was identified as an epigenetic profile associated with low
risk of metastasis. Parallel gene expression analyses identified genes with both significant
hypermethylation and down-regulation in B-CIMP tumours, including those involved in
epithelial-mesenchymal transition (EMT), such as LYN, MMP7, KLK10 and WNT6 and the
genes in the B-CIMP repression signature showed genes whose differential expression
correlated with prognosis across several BC cohorts [89].
6. HDAC inhibitors and breast cancer
As we mentioned previously, abnormal HDAC activity has been documented in a variety of
tumour types and led to the development of HDAC inhibitors as anticancer therapeutics.
Currently available HDAC inhibitors target a variety of HDAC isoenzymes with class 1
(HDAC 1, 2, 3 and 8), class 2 (HDAC 4–7 and 9–10), and class 4 (HDAC 11) activity. Modest
clinical benefits were previously reported with relatively weak HDAC inhibitors such as
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valproic acid and phenylbutyrate in advanced solid tumours or hematologic malignancies [89].
Laboratory research conducted to date supports the investigation of HDAC inhibitors for the
treatment of breast cancer. Recently, vorinostat as HDAC inhibitor induces differentiation or
arrests growth of a wide variety of human carcinoma cells including breast cancer cells
[90].Vorinostat also reduced tumour incidence in NMU-induced rat mammary tumourigene‐
sis by 40 % [91]. In vitro studies demonstrated that vorinostat inhibits clonogenic growth of
both ER-positive and ER-negative breast cancer cell lines by inducing G1 and G2/M cell cycle
arrest and subsequent apoptosis [92].
The ability of the HDAC inhibitors to relieve transcriptional repression in preclinical breast
cancer models has also been investigated. The accumulation of acetylated H3 and H4 histone
tails in conjunction with re-expression of a functional ER in ER-negative breast cancer cell lines
has been observed with a novel HDAC inhibitor known as scriptaid [93].Treatment of ER-
negative breast cancer cell lines with vorinostat is associated with reactivation of silenced ER,
as well as down regulation of DNMT1 and EGFR protein expression [94]. The significance of
an epigenetically reactivated ER was demonstrated when tamoxifen sensitivity was restored
in the ER-negative MDA-MB-231 breast cancer cells following treatment with both HDAC
(trichostatin A) and DNMT inhibitors (DAC) [95]. Entinostat has been shown to induce not
only re-expression of ERα, but also the androgen receptor and the aromatase enzyme (CYP19)
both in vitro and in triple-negative breast cancer xenografts [96]. In addition, the combination
ofletrozole and entinostat resulted in a significant and durable reduction in the xenograft
tumour volume when compared to treatment with either agent alone. These experiments have
provided the strong rationale for combining epigenetic modifiers with hormonal therapy in
breast cancer clinical trials [96]. Interestingly, many of these studies also indicate that a strategy
which combines HDAC and DNMT inhibitors is more efficacious than either agent alone with
respect to both re-expression of silenced genes and restoration of response to tamoxifen and
aromatase inhibitors [93.97].
Moreover, pretreatment of various tumour cell lines with HDAC inhibitors increases the
cytotoxicity of chemotherapy. Administering the HDAC inhibitor after chemotherapy did not
achieve the same results, suggesting that pretreatment with these agents may open the
chromatin structure and thus facilitate an enhanced anti-cancer effect of chemotherapy drugs
that target DNA [98]. In breast cancer cell lines with amplification and overexpression of HER2,
HDAC inhibitor use depleted HER2 by attenuation of its mRNA levels and promotion of
proteosomal degradation. HDAC inhibition also had been reported to enhance apoptosis
induction by trastuzumab, docetaxel, epothilone B, and gemcitabine [99]. HDAC inhibitors
also significantly enhance trastuzumab-induced growth inhibition in trastuzumab-sensitive,
HER2-overexpressing breast cancer cells, providing a strong rationale for clinical studies with
this combination in patients with HER2-positive disease [100].
Additionally, HDAC inhibitors such as entinostat or valproic acid, have been tested in breast
cancer cells and efficiently restored both ERα expression and letrozole sensibility in ER-BC in
vitro and in vivo [101,102].The association of HDAC inhibitors or 5-azadeoxycytidine with a
treatment inducing overexpression of TFAP2C might improve ESR1 expression in ER-patients.
A combined HDAC inhibitors and 5-azadeoxycytidine treatment induces the most significant
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increase in ERα content. Surprisingly however, addition of tamoxifen does not produce a
tumourigenic response in ER-BC cells demonstrated that a better response to tamoxifen in BC
cells, correlated with a lower level of the RNA-stabilizing HuR protein [103]. Tamoxifen
treatment increased HuR content, and contributed to its own resistance while HDAC inhibi‐
tors /5-azadeoxycytidine decreased HuR. Preliminary treatment with HDAC inhibitors /5-
azadeoxycytidine was given before delivering tamoxifen to attempt to obtain the best
tamoxifen sensitivity. The precise roles of tamoxifen are complex: although it competes with
17β-estradiol to bind to ERα, ERα bound to tamoxifen is still able to target the TFF1 (also called
pS2) promoter without constitutive activation of gene transcription. The loss of transcriptional
activity of the tamoxifen-ERα complex is mediated by changes in the balance of co-activators/
co-repressors and ERα-interacting partners [104].
7. DNMTs inhibitors and breast cancer
The human DNMTs 1,  3A,  and 3B coordinate  mRNA expression in  normal  tissues  and
overexpression  in  tumours  and  the  expression  levels  of  these  DNMTs  are  reportedly
elevated in breast cancer [105,106]. The mean levels of DNMT1, DNMT3a, and DNMT3b
overexpression  have  turned out  to  be  quite  similar  among different  tumour  types.  The
DNMT3b gene has shown the highest  range of  expression (81.8 for  DNMT3a compared
with 16.6 and 14 for DNMT1 and DNMT3a, respectively). About 30% of patients revealed
overexpression  of  DNMT3b  in  the  tumour  tissue  as  compared  to  normal  breast  tissue.
Taking only these overexpressing tumours into account, the DNMT3b expression change
was 82-fold, thus being significantly higher [106]. Interestingly, DNMT1 and DNMT3a were
overexpressed in only 5 and 3% of breast carcinomas [107].  As a result of these studies,
DNMT3b plays the predominant role over DNMT3a and DNMT1 in breast tumourigene‐
sis. This is consistent with a recent study in breast cancer cell lines, which demonstrated a
strong correlation between total DNMT activity and overexpression of DNMT3b, but not
with the expression of DNMT3a or DNMT1 [107,108].
Cancer was the first group of diseases to be associated with DNA methylation and to be
considered for DNA-methylation-targeted therapeutics, and it serves as a prototype for
determining the role of DNA methylation and DNA-methylation-targeted therapeutics in
other diseases [109]. As we mentioned previously, several types of aberration in DNA
methylation and in the proteins involved in DNA methylation occur in cancer: hypermethy‐
lation of tumour suppressor genes, aberrant expression of DNMT1 and other DNMTs, and
hypomethylation of unique genes and repetitive sequences [110,111]. Silencing of tumour
suppressor genes by DNA methylation provides a powerful molecular mechanism by which
DNA methylation can trigger cancer, and also provides a rationale for therapeutics aimed at
inhibition of DNA methylation and re-expression of silenced tumour suppressor genes.
Multiple genes are hypermethylatedin breast cancer compared to non-cancerous tissue [112].
These include genes involved in evasion of apoptosis (RASSF1A, HOXA5, TWIST1), limitless
replication potential (CCND2, p16, BRCA1, RARβ), growth (ERα, PGR), and tissue invasion
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and metastasis (CDH1) [113]. These genes are not only hypermethylated in tumour cells, but
show increased epigenetic silencing in normal epithelium surrounding the tumour site.
Unlike genetic alterations which are almost impossible to revert, DNA methylation is a
reversible event. Reactivation of hypermethylated tumour-suppressor genes can be consid‐
ered as a possible therapeutic target which will lead to develop pharmacological inhibitors of
DNA methylation. Moreover, the use of DNMT inhibitors is good tools for cancer treatment
because the restoration of expression of tumour-suppressor genes could restore the protective
effect of these genes on tumour divisions [114]. The nucleoside analogues, 5-azacytidine
(vidaza or AZA,) and 5-aza-2’-deoxycytidine (decitabine or DAC) are two DNMT inhibitors
that are effective hypomethylating agent that inhibit cell proliferation [115]. These two drugs
represent the two most prominent DNMT inhibitors being under preclinical and clinical
investigation for over 30 years [116]. Moreover, these agents are pro-drugs that need to be
incorporated into DNA to act as inhibitors of DNMTs [116]. The nucleoside analogues are first
phosphorylated to the triphosphate nucleotide and incorporated into DNA during DNA
synthesis. DNMT1 forms a covalent bond with the carbon at position 6 of the cytosine as well
as 5-aza-cytosine ring. Under normal conditions, as mentioned previously, the enzyme
transfers the methyl group from SAMe to the fifth carbon position of the cytosine ring. This
enables the release of the enzyme from its covalent bond with cytosine. When a 5′-aza-cytosine
ring replaces cytosine in the DNA, the methyl transfer does not take place and the DNMT is
trapped on the DNA (Figure 3). The replication fork progresses in the absence of DNMT1
resulting in passive loss of DNA methylation in the nascent strand but not the template [116].
Because they are cytidine analogues, both agents are incorporated into DNA after activation
to a triphosphate moiety. After formation of an irreversible complex with DNMT1, degrada‐
tion of the enzyme occurs [117]. This prevents methylation of daughter DNA in CpG islands
during DNA replication. In addition, AZA (but not DAC) is converted into a ribonucleoside
moiety and is incorporated into RNA, interfering with protein translation. At low concentra‐
tions (e.g. 30nM DAC, 300nM AZA), these inhibitors exhibit potent DNA hypomethylation
properties, whereas high concentrations (≈3–10 μM) are cytotoxic [119]. The doses of AZA and
DAC that were employed in many of the early clinical trials in solid tumours were cytotoxic,
reflecting maximum tolerated doses, which likely accounts for the excessive toxicity, and
possibly also to lack of overall efficacy, observed in these studies [120]. Previous study
indicated that the DNMT inhibitors were associated with response rates as high as 18% in
breast cancer [120]. The doses of AZA that were employed in these studies, however, were far
higher than doses used in clinical trials today and likely exerted cytotoxic activity as opposed
to relief of transcriptional repression as an anti-cancer strategy [120].
Current clinical studies with administration of DNMT inhibitors at the presumed optimal
epigenetic dose aim to elucidate the biological effects of these agents, and to assess clinical
efficacy, alone or in combination with other anti-cancer agents. The ability of single agent AZA
to induce expression of the ER and PR genes in patients with triple-negative breast cancer who
are awaiting definitive breast cancer surgery is under investigation using a 75 mg/m2/day
dosing schedule [121]. Based on the preclinical evidence previously described which suggests
that a combination of epigenetic modifiers may be more successful in re-expression of silenced
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genes and restoration of hormonal therapy responsiveness, patients with advanced triple-
negative and hormone-resistant breast cancer are being enrolled in an ongoing multi-center
phase 2 clinical trial and receive the combination of low dose AZA (40 mg/m2) on days 1–5 and
8–10, and entinostat 7 mg on days 3 and 10 of a 28 day cycle. Tumour biopsies prior to and
after therapy are collected to assess modulation of candidate gene methylation and expression,
such as the ER gene. Patients may transition to an optional continuation phase at the time of
disease progression in which the same epigenetic therapy is administered with the addition
of hormonal therapy [122].
The DNMT inhibitors combination with standard chemotherapy has not been extensively
evaluated in the breast cancer setting and preclinical evidence have shown the AZA could
overcome platinum resistance through DNA hypomethylation, patients with both platinum
resistant and refractory ovarian cancer received the combination of AZA and carboplatin after
being enrolled [122,123]. Since DNMT inhibitors like AZA and DAC are known to be effective
in the clinic for diseases like myelodys plastic syndromes that may result in part from tran‐
scriptional dysregulation due to epigenetic changes, there is interest in developing novel
DNMT inhibitors that would be more effective and less toxic. One such putative agent is
zebularine, a cytidine which has been reported to prevent early tumour development and also
to inhibit growth of mammary gland tumours and breast cancer cells lines [124,125]. Zebular‐
ine is a novel DNMT inhibitor, which was developed as a more stable and less toxic drug [126].
Zebularine, similar to AZA-CR and 5-AZA-CdR, incorporates into DNA and forms a covalent
irreversible complex with DNMT preventing the enzyme from methylating position 5 of
cytosines clustered in regulatory CpG islands [127]. Recent studies showed the ability of
zebularine to sustain the demethylation state of the 5′ region of the tumour suppressor gene
CDKN2A/p16 and other methylated genes in T24, HCT15, CFPAC-1, SW48, and HT-29 cells
[127]. It was also reported that zebularine inhibits growth of cancer cell lines but not normal
cells [128].
Zebularine acts as a cytidine analogue containing a 2-(1H)-pyrimidinone ring that was
originally developed as a cytidine deaminase inhibitor to prevent deamination of nucleoside
analogues [129,130]. Zebularine is also a versatile starting material for the synthesis of complex
nucleosides and is a mechanism based DNA cytosine methyltransferase inhibitor [131]. It acts
primarily as a trap for DNMT protein by forming tight covalent complexes between DNMT
protein and zebularine-substituted DNA [132]. In contrast, to other DNMT inhibitors, it has
low toxicity in most tested cell lines and is quite stable with a half-life of 510 h at pH 7.4 [131,
133,134]. Because of its low toxicity, continuous administration of effective doses of zebularine
alone or in combination with other DNMT inhibitors is feasible and this can result in the
enhanced re-expression of epigenetically silenced genes in cancer cells [128].
Zebularine treatment led to increased p21 protein expression coupled with decreased cyclin
B and D protein expression in MCF-7 cells and an increased percentage of cells in S-phase that
indicates a zebularine induced S-phase arrest [135].This finding suggests errors in chromatin
assembly that contribute to genome instability [136]. S-phase arrest can also be triggered by
repression of histone synthesis in human cells [137]. The genomic instability induced by
DNMT1 down regulation and repression of histone synthesis triggers the activation of S-phase
DNA Methylation
http://dx.doi.org/10.5772/59467
41
check point proteins like p21 (in MCF-7 cells) and/or down regulates cyclin-D to permit DNA
repair before entering G2 phase.
The zebularine-mediated decrease in expression of global acetylated histones observed in our
studies further supports our hypothesis. Several preclinical studies have evaluated zebularine
as a possible therapeutic in cancer cell lines. Zebularine preferentially incorporates into DNA,
leading to cell growth inhibition and increased expression of cell cycle regulatory genes in
cancer cell lines compared with normal fibroblasts [135]. Additionally, to determine the ability
of zebularine to prevent or treat breast cancer, Min et al, 2012 tested if daily oral treatment with
zebularine affects mammary tumour growth in these MMTV-PyMT mice [124]. They observed
a significant delay in tumour growth and a reduction of total tumour burden in the zebularine-
treated mice. They have reported that the depletion of DNMTs in tumours excised from
zebularine-treated mice and identified upregulation of 12 genes previously characterized as
silenced by DNA hypermethylation. Zebularine treatment was shown to be associated with a
dose-dependent depletion of DNMT1, DNMT3a, and DNMT3b proteins in the breast cancer
cell lines MCF-7 and MDA-MB-231 [124]. Zebularine also depletes DNMT1 in T24 bladder
carcinoma cells after 24 hours of treatment and partially depletes DNMT3b after 3 days of drug
exposure [128]. Recently, Chen et al, (2012) have proofed in in vivo study that DNMT1 was
depleted, and DNMT3b was significantly lowered (50% depletion) in the mammary tumours
derived from zebularine-treated mice as compared with untreated mice [138]. Regardless of
the mechanism of tumour growth inhibition, tumour cells eventually develop resistance to
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Figure 3. Activation of gene expression by nucleoside analogues, 5-azacytidine (vidaza or AZA,) and 5-aza-2’-deoxycy‐
tidine (decitabine or DAC), both are DNMTs inhibitors. (A) In active transcription is characterized by the presence of
methylated cytosines within CpG dinucleotides (CH3) which is sustained by DNMTs. (B) When a 5′-aza-cytosine ring
replaces cytosine in the DNA, the methyl transfer does not take place and the DNMT is trapped on the DNA and the
gene expression could restored again.
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zebularine treatment. Because it has been shown that zebularine and the HDAC inhibitor
depsipeptide have a synergistic effect on the inhibition of breast cancer growth a combinatorial
treatment with DNMT inhibitors and a combinatorial treatment with DNMT inhibitors and
HDAC inhibitors may be warranted to overcome resistance to single-drug therapy.
Moreover, zebularine have been reported to depleted expression of all three DNMT proteins
post-transcriptionally in both breast cancer cell lines at most doses tested. It has been reported
that human cancer cells lacking DNMT1 or DNMT3b retain significant global methylation and
gene silencing, but those lacking both DNMT1 and DNMT3b had >95% reduction in genomic
DNA methylation and virtually absent DNMT activity [135]. The zebularine treatment
specifically targets DNMT1, and reduced DNMT 3a and 3b protein expression, implying that
treated cells may still retain substantial methylation [139]. Another study observed similar
results in T24 bladder cancer cells continuously treated with zebularine for 40 days. In these
cells zebularine had no effect on the expression of DNMT1, 3a or 3b mRNA but complete loss
of DNMT1 and partial depletion of DNMT 3a and 3b protein were observed [128].
Previous findings observed that ER can be epigenetically silenced in some human breast cancer
cell lines and HDAC or DNMT inhibitors could reexpress functional ER in ER negative breast
cancer cells [140,141]. Further investigation demonstrated that treatment of ER negative MDA-
MB-231 breast cancer cells with zebularine results in functional ER reactivation as manifested
by expression of ER mRNA and its target gene, PR. This has been reported with a dose as low
as 50μM, far lower than doses that induced apoptosis. Chromatin immunoprecipitation
analysis of the ER promoter in zebularine-treated cells showed characteristics of an active
chromatin as manifested by accumulation of acetylated H3 and H4 and release of DNMT1, 3a
and 3b from the ER promoter region. Although reexpression of ER with zebularine was not as
robust as with 5-azaDc, the low toxicity could enable continuous administration for sustained
re-expression of ER cells [141].
However, several studies have shown that zebularine has some potential limitations such as
less potent than the two FDA-approved DNMT inhibitors, azaC and 5-azaDc [133]. It is
hypothesized that the reduced inhibitor potency is due to sequestration of the drug by cytidine
deaminase, competitive inhibition of zebularine incorporation into DNA by increased cytidine
and deoxycytidine that accumulate as a consequence of its cytidine deaminase properties, and
preferential incorporation of zebularine into RNA over DNA [142]. For these reasons, the drug
is effective only at very high doses, making administration more problematic. Its efficacy
combined with a low toxicity profile makes it an attractive agent for combination or sequential
therapy with other DNMT or HDAC inhibitors [143].
8. Combination of DNMT inhibitors
Based on the preclinical evidence previously described which suggests that a combination of
epigenetic modifiers may be more successful in re-expression of silenced genes and restoration
of hormonal therapy responsiveness, we have mentioned previously that the patients with
advanced triple-negative and hormone-resistant breast cancer are being enrolled in an ongoing
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multi-center phase 2 clinical trial and receive the combination of low dose of AZA [122].
Tumour biopsies prior to and after therapy are collected to assess modulation of candidate
gene methylation and expression, such as the ER. Patients may transition to an optional
continuation phase at the time of disease progression in which the same epigenetic therapy is
administered with the addition of hormonal therapy [123]. Indeed, in a recently published trial
exploring the combination of AZA and entinostat in advanced non-small cell lung cancer
patients, investigators observed that the regimen was well tolerated and associated with a
number of objective responses [144]. These included a complete response as well as a partial
response in a patient without progression of disease for 2 years after completing the clinical
trial. Interestingly, a number of patients were found to have unexpected major objective
responses to subsequent anti-cancer strategies, raising the question as to whether these agents
may prime tumour cells to respond to subsequent therapies. A phase 1/2 Canadian trial
investigating the combination of decitabine and vorinostat in patients with advanced solid
tumours or hematologic malignancies has also indicated clinical activity. Stabilization of
disease for 4 or more cycles was observed in 29 % evaluable patients; two of these patients had
metastatic breast cancer [145].
Moreover, cytidine deaminase destabilizes DNMT inhibitors like 5-azaDc, resulting in
complete loss of their antineoplastic ability [146]. Hence administration of cytidine deaminase
inhibitors like zebularine should theoretically potentiate therapeutic effects of 5-azaDc by
slowing its degradation and stabilizing activity. Indeed, the combination of 5-aza-Dc and
zebularine produced greater inhibition in cell proliferation and clonogenicity than either drug
alone in leukemic L1210 and HL-60 cell lines [147]. Similarly, treatment of the AML-193 acute
myeloid leukemic cell line, which has a densely methylated p15INK4B CpG island, with
zebularine followed by the HDAC inhibitor, trichostatin-A, synergistically enhanced
p15INK4B expression [134]. Consistent with these results, the combination of 50μMzebularine
and 1μM 5-azaDc in breast cancer cells significantly inhibited cell proliferation compared with
either drug alone. Similarly, zebularine significantly inhibited cell proliferation and colony
formation in combination with low doses of vorinostat. Cheishvili et al, (2014) have investi‐
gated the combination of methylated DNA binding protein 2 (MBD2) depletion and DNMT
inhibitor 5-azaCdR in breast cancer cells results in a combined effect in vitro and in vivo,
enhancing tumour growth arrest on one hand while inhibiting invasiveness triggered by 5-
azaCdR on the other hand. The combined treatment of MBD2 depletion and 5-azaCdR
suppresses and augments distinct gene networks that are induced by DNMT inhibition alone.
These data point to a potential new approach in targeting the DNA methylation machinery by
combination of MBD2 and DNMT inhibitors [148].
The combination of DNMT inhibitors with standard chemotherapy has not been extensively
evaluated in the breast cancer setting. Based on strong preclinical evidence that the addition
of AZA could overcome platinum resistance through DNA hypomethylation, patients with
both platinum resistant and refractory ovarian cancer received the combination of AZA and
carboplatin after being enrolled into a phase 1b/2 study. The overall response rate of 22 % was
observed in the platinum-resistant patients (disease progression within 6 months of platinum,
n=18) suggesting that further evaluation of the combination was warranted [149]. Whether
combining DNMT inhibitors with standard therapies or novel agents will result in clinical
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benefit for patients with breast cancer remains to be seen. In the meantime, robust preclinical
data should support the development of new concepts in order to maximize the chance of
success with these agents in the solid tumour arena.
9. Conclusion
Future studies need to include a more detailed investigation of the methylation differences
between breast cancer subtypes to determine whether there is a methylation signature that can
identify breast cancer subtypes. It is also possible that DNA methylation subtypes are different
to the subtypes identified by gene expression and may provide additional information that
assists in the clinical setting. Further research is required to delineate these options and
determine how subtypes identified by DNA methylation profiling differ to subtypes identified
by gene expression. Laboratory studies have shown that AZA and DAC optimally inhibit DNA
methylation when used at lower than cytotoxic doses with prolonged exposures. The exact
impact of using epigenetic modifiers at an optimally epigenetic dose instead of a cytotoxic dose
is yet unknown in solid tumours, despite the supposition that anti-cancer activity will be
enhanced. Ongoing clinical trials in breast cancer patients aim to elucidate this question.
Optimizing the use of the clinically available epigenetic modifiers is clearly important. An oral
form of AZA is currently in development which may be far more convenient for patients than
the intravenous and subcutaneous routes employed at this time. A number of new agents are
also in development which may circumvent some of the limitations of the currently available
drugs such as their in vivo deamination by cytidine deaminase and tendency to be subject to
drug resistance.
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